Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20267 Citations
TesofensineSmall moleculeNo amino acid sequence. Icon reflects category theme only.Tesofensine is a triple monoamine reuptake inhibitor that produced 9.2% body weight loss in 24 weeks at 0.5 mg daily. Oral capsule, no injection. Not FDA-approved; Phase 3 complete in Mexico. Heart rate monitoring required during the full treatment course.
0.25mcg · Daily
Summary: Add 0mL BAC water to your 0.25mg vial. Draw to < 0.1 units on a U-100 syringe for a 0.25mcg dose. This vial will last 0 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 0.25mg | Daily |
| Moderate | 0.5mg | Daily |
| Aggressive | 1mg | Daily |
This one is oral, not injectable. No reconstitution math, no bacteriostatic water, no syringes. You're taking a capsule each morning. Start at 0.25 mg daily for the first 2 to 4 weeks. The half-life is around 9 days, so you won't reach steady state until roughly week 4 or 5. Don't judge whether it's working before then. The active metabolite M1 has a 16-day half-life on top of that. Effects build slowly and linger long after your last dose. Take it before 9 AM. This is non-negotiable if you value sleep. Even noon dosing causes insomnia for most people. Monitor your resting heart rate at baseline and weekly for the first month. If it jumps more than 10 bpm or crosses 100 bpm, hold at the current dose and reassess. Don't rapidly stop and restart; the long half-life means plasma levels shift very slowly. Gray-market sourcing is the current reality. No US compounding pharmacy pathway exists. Verify lot-specific COAs with HPLC purity data before buying anything.
Dosing based on Phase 3 NeuroSearch trial: tesofensine in adults with obesity (2009) — 12 published references.View all sources →
Cross-check your Tesofensine reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Tesofensine is a triple monoamine reuptake inhibitor that produced 9.2% body weight loss in 24 weeks at 0.5 mg daily. Oral capsule, no injection. Not FDA-approved; Phase 3 complete in Mexico. Heart rate monitoring required during the full treatment course.
